Name: ESMO 2024 Insights: POD1UM-303/InterAACT 2 Study: Retifanlimab With Carboplatin-Paclitaxel in Pts With Inoperable Locally Recurrent or Metastatic SCC of the Anal Canal Not Previously Treated With Systemic Chemo
Uploaded: 2025-03-29T05:25:17+00:00
Duration: 15 min 21 s

Find latest Colon Cancer videos · 400+ videos

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: POD1UM-303/InterAACT 2 Study: Retifanlimab With Carboplatin-Paclitaxel in Pts With Inoperable Locally Recurrent or Metastatic SCC of the Anal Canal Not Previously Treated With Systemic Chemo

By 2024 ESMO Annual Meeting Insights Hub FEATURING Sheela Rao

60 views

March 28, 2025

Disclaimer: On May 15, 2025, the FDA has approved retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA has also approved retifanlimab as monotherapy for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

Comments 0